- Prestige Consumer Healthcare reported second quarter 2026 results with sales of US$332.9 million and revenue of US$336.31 million, while net income was US$25.3 million and diluted EPS from continuing operations was US$0.53.
- The mix of higher sales and revenue alongside lower net income and earnings per share highlights growing cost or margin pressures within Prestige Consumer Healthcare's portfolio.
- We will now examine how Prestige Consumer Healthcare's investment narrative is affected by higher quarterly sales alongside weaker earnings per share.
Scan beyond Prestige Consumer Healthcare and line up similar consumer-focused stocks facing margin pressure with our curated 35 high quality undervalued stocks list.
Prestige Consumer Healthcare Investment Narrative Recap
To stay comfortable owning Prestige Consumer Healthcare, you need to believe the branded OTC portfolio can convert higher sales into healthier profitability again. The latest quarter shows strong top line at US$332.9 million in sales and US$336.31 million in revenue, yet net income and EPS are weaker, which keeps the focus squarely on cost discipline and mix.
The near term catalyst is execution on margin repair while integrating acquisitions and rebuilding eye care capacity. The biggest risk is that supply chain fixes, pricing and cost control do not show up in cleaner earnings, which would leave net income under pressure and make the current debt load feel heavier than planned.
The most relevant update here is the six month fiscal 2027 performance. Prestige Consumer Healthcare reported US$593.23 million in sales and US$602.02 million in revenue for the period, with net income of US$54.47 million and diluted EPS from continuing operations of US$1.14.
That half year picture gives you a broader read on how margin pressure is playing out across the portfolio, not just in a single quarter. It also matters for key catalysts such as free cash flow and deleveraging, because sustained compression in earnings would make the existing interest burden and planned balance sheet improvement harder to deliver.
Prestige Consumer Healthcare's current narrative centers on analysts expecting revenue to reach US$1.3b and earnings to come to US$227.7 million by 2029. This outlook is based on a projected 6.1% yearly revenue growth rate and a move from US$172.0 million in earnings today to that US$227.7 million figure, which represents an increase of about US$55.7 million in profit over the period.
Uncover why Prestige Consumer Healthcare's fair value indicates a 27% potential upside to its current price before that valuation gap closes.
Exploring Other Perspectives
Some of the lowest Prestige Consumer Healthcare analysts lean hard into acquisition drag as the main risk. Before this earnings release, they were only pencilling in around 1.7% yearly revenue growth and about US$1.2b of sales by 2029. That is a far more cautious script, and this quarter’s margin squeeze may push those views even further apart.
Explore another Prestige Consumer Healthcare fair value estimate, including one that suggests it could be worth just $67.80!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.
- A great starting point for your Prestige Consumer Healthcare research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Prestige Consumer Healthcare. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Prestige Consumer Healthcare's overall financial health at a glance.
Looking For More Investment Ideas Beyond Prestige Consumer Healthcare?
If the Prestige Consumer Healthcare story has sharpened your view on margins, cash generation and balance sheet strength, it can be useful to compare it with stocks that share some of those traits or offer a very different risk profile. The Simply Wall St Screener is built for exactly that kind of side by side work, letting you filter by quality markers, valuation and resilience so you can build a watchlist that actually fits your own goals and risk tolerance.
- If you care most about resilience and capital preservation, start with companies that score well on stability and risk and see what stands out in the 31 resilient stocks with low risk scores.
- For investors who want a mix of financial strength and cleaner balance sheets, you can filter for strong fundamentals using the list of solid balance sheet and fundamentals (24 results).
- If you prefer earlier stage opportunities that still show robust underlying figures, focus on compact market caps with healthier profiles through the 7 elite penny stocks with strong financials.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com